Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Drug efficacy

Naloxegol effective in treating opioid-induced constipation

Naloxegol has shown efficacy in two phase III clinical trials.

Osteoarthritis illustration (Talik/

Opioid-induced constipation is a common side-effect of drugs to treat osteoarthritis

Naloxegol, designed for the treatment of opioid-induced constipation (OIC), has shown efficacy in two phase III clinical trials, published in The New England Journal of Medicine.

In the trials, which included 1,352 outpatients with non-cancer pain and opioid-induced constipation, naloxegol 25mg/day taken orally achieved a better 12-week response rate than placebo (response was defined as three or more spontaneous bowel movements per week).

OIC is a common side effect of drugs used to treat osteoarthritis and chronic back pain. Reported pain and level of opioid dose were similar between users of naloxegol and placebo. The most commonly reported adverse events with naloxegol were abdominal pain, diarrhoea, nausea and flatulence.

Naloxegol is marketed by AstraZeneca and is currently being appraised by the National Institute for Health and Care Excellence. It is a pegylated derivative of the μ-opioid receptor antagonist naloxone.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20065359

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.